Table 2 Sensitivity and specificity of autoantibodies before onset of disease symptoms in individuals who later developed SLEa
From: Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden
Presymptomatic individuals | |||||||
|---|---|---|---|---|---|---|---|
Autoantibodies | Sensitivity, n(%) | Specificity n% | Controls, n(%) | OR | 95% CI | Pvalueb | LR |
ANA | 16 (45.7)*** | 95.0 | 10 (6.7) | 11.5 | 4.54 to 28.87 | <0.0001 | 9.14 |
dsDNA | 7 (20.0)*** | 98.7 | 2 (1.4) | 18.13 | 3.58 to 91.84 | <0.0001 | 15.38 |
Ro/SSA | 7 (20.0)*** | 97.4 | 4 (2.7) | 8.94 | 2.45 to 32.58 | <0.0001 | 5.56 |
Histone | 5 (14.3)** | 98.0 | 3 (2.0) | 8.06 | 1.83 to 35.54 | <0.001 | 7.15 |
RNP | 4 (11.4)** | 98.7 | 2 (1.4) | 9.36 | 1.64 to 53.36 | <0.01 | 8.77 |
La/SSB | 3 (8.6)** | 100 | 0 | ||||
Jo-1 | 3 (8.6)* | 98.7 | 2 (1.4) | 6.80 | 1.09 to 42.36 | <0.05 | 6.62 |
Scl-70 | 2 (5.7) | 99.3 | 1 (0.7) | 8.85 | 0.78 to 100.51 | ns | 8.0 |
Sm | 1 (2.9) | 100 | 0 | ||||
Centromere protein B | (2.9) | 98.7 | 1 (0.7) | 4.29 | 0.26 to 70.39 | ns | 1.54 |